AT ASCO 2017

CHICAGO (FRONTLINE MEDICAL NEWS) – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic leukemia (CLL), based on results from the phase 2 CALGB 10404 trial.

This unique survival plateau indicates future studies should continue to examine the role of lenalidomide, compared with fludarabine plus rituximab therapy, as well as the incorporation of lenalidomide into other novel treatment regimens, Amy Ruppert, MAS, said at the annual meeting of the American Society of Clinical Oncology.

In the study , patients with untreated CLL were randomized to one of three treatment arms: 123 received treatment with fludarabine plus rituximab (FR), 109 got FR and six monthly consolidative treatments of lenalidomide (FR+L), and 110 got fludarabine plus rituximab and cyclophosphamide (FCR).

All patients received 6 months of FR or FCR therapy, then patients underwent full staging. At 10 months, patients who had been randomized to the FR + lenalidomide group received lenalidomide 5 mg on days 1-21 of the first 28 day cycle and lenalidomide 10 mg on days 1-21 of the subsequent 5 cycles. At 18 months, patients in the FR+L group underwent full staging, and all patients underwent full staging at 24 months.

Based on pretreatment central interphase cytogenetic screening, patients who had del(11q22.3) in at least 20% of their cells were excluded from the primary analysis of 2-year progression-free survival.

Median progression-free survival was significantly shorter with FR, compared with FR+L (P = .03) and FCR (P less than .01), at 43 months (95% CI, 33-50), 66 months (95% CI, 45-not reached), and 78 months (95% CI, 58-not reached), respectively.

Median overall survival has not been reached for any arm of the study. While overall survival was similar across all arms at 1, 2, and 3 years of follow-up, there was a plateau in overall survival with no events seen beyond 41 months in the FR+L arm. Events continued to occur in the FR and FCR arms, reported Ms. Ruppert of the Comprehensive Cancer Center at Ohio State University, Columbus. At 48 months, the hazard ratio for overall survival in FR+L vs. FR was 0.27 (95% CI, 0.10-0.70; P = .01).

Ms. Ruppert had no financial disclosures. The study is sponsored by the National Cancer Institute and Celgene.

mdales@frontlinemedcom.com

On Twitter @maryjodales

Ads

You May Also Like

C6 EIA testing can guide Lyme disease treatment in children

FROM CLINICAL INFECTIOUS DISEASES The C6 Lyme enzyme immunoassay is an effective diagnostic tool ...

ATRA-arsenic ‘new standard of care’ for APL

FROM JOURNAL OF CLINICAL ONCOLOGY The combination of all-trans­-retinoic acid (ATRA) and arsenic trioxide ...